Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03920267
Other study ID # IM011-074
Secondary ID 2018-003471-35
Status Active, not recruiting
Phase Phase 2
First received
Last updated
Start date March 26, 2019
Est. completion date March 31, 2025

Study information

Verified date May 2024
Source Bristol-Myers Squibb
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The main objective of the trial is to characterize the long-term safety and tolerability of BMS-986165 in subjects with Systemic Lupus Erythematosus (SLE).


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 261
Est. completion date March 31, 2025
Est. primary completion date March 31, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - Completion of SLE Study (NCT03252587) through the protocol-required treatment period, and currently receiving blinded study drug. Note: If a subject is not receiving blinded study drug due to exceptional circumstances (eg, missed investigational product [IP] due to COVID-19 pandemic, delays in study approval, etc), the subject may be allowed to enroll with approval from the BMS Clinical Trial Physician or designee. Exclusion Criteria: - Any disease or medical condition that, in the opinion of the investigator, would make the subject unsuitable for this study, would interfere with the interpretation of subject safety or study results, or considered unsuitable by the investigator for any other reason - Evidence of active tuberculosis (TB) Other protocol-defined inclusion/exclusion criteria apply

Study Design


Intervention

Drug:
BMS-986165
Specified dose on specified days

Locations

Country Name City State
Argentina Local Institution - 0100 Caba
Argentina Clinica Adventista Belgrano Ciudad Autonoma de Buenos Aires Buenos Aires
Argentina Local Institution - 0125 Ciudad Autonoma de Buenos Aires Buenos Aires
Argentina Local Institution - 0122 Cordoba
Argentina Local Institution - 0095 Mendoza
Argentina Local Institution - 0098 Rosario Santa FE
Argentina Local Institution - 0091 San Miguel De Tucum Tucuman
Brazil Local Institution - 0120 Curitiba Parana
Brazil Local Institution - 0118 Goi? Goias
Brazil Local Institution - 0106 Juiz de Fora Minas Gerais
Brazil Local Institution - 0107 Porto Alegre RIO Grande DO SUL
Brazil Local Institution - 0116 Salvador Bahia
Brazil Local Institution - 0111 Sao Bernardo do Campo SAO Paulo
Brazil Local Institution - 0105 Sao Paulo
Canada University of Calgary Calgary Alberta
Canada Local Institution - 0136 Toronto Ontario
Colombia Local Institution - 0108 Barranquilla
Colombia Local Institution - 0101 Bogot
Colombia Local Institution - 0103 Chia
Colombia Local Institution - 0096 Zipaquira
Hungary Local Institution - 0039 Debrecen
Hungary Local Institution - 0038 Gyula
Hungary Local Institution - 0045 Szeged
Japan National Hospital Organization Chibahigashi National Hospital Chiba-shi Chiba
Japan Local Institution - 0065 Chuo-ku Tokyo
Japan Local Institution - 0092 Kitakyushu Fukuoka
Japan Hokkaido University Hospital Sapporo Hokkaido
Japan Local Institution - 0119 Sapporo-Shi Hokkaido
Japan Local Institution - 0063 Sendai Miyagi
Japan Local Institution - 0069 Shimotsuke-city Tochigi
Japan Local Institution - 0066 Tokyo
Japan Local Institution - 0078 Tokyo
Japan Local Institution - 0093 Tokyo
Korea, Republic of Local Institution Seoul
Korea, Republic of Local Institution - 0053 Suwon
Mexico Local Institution - 0080 Leon Guanajuato
Mexico Local Institution - 0086 Leon Guanajuato
Mexico Local Institution - 0087 Mexico City Distrito Federal
Mexico Local Institution - 0084 Monterrey Nuevo LEON
Mexico Local Institution - 0082 San Luis Potosi
Mexico Investigacion Biomedica para el Desarrollo de Farmacos S.A. de C.V. Zapopan Jalisco
Poland Local Institution - 0025 Bydgoszcz
Poland Local Institution - 0015 Koscian
Poland Local Institution - 0014 Krakow
Poland Local Institution - 0018 Krakow
Poland Local Institution - 0027 Krakow
Poland Local Institution - 0016 Lublin
Poland Local Institution - 0024 Poznan
Poland Local Institution - 0029 Sosnowiec
Poland Local Institution - 0019 Warsaw
Poland Local Institution - 0022 Warszawa
Poland Local Institution - 0010 Wroclaw
Poland Local Institution - 0023 Wroclaw
Romania Local Institution - 0033 Brasov
Romania Local Institution - 0004 Galati
Romania Local Institution - 0002 Ramnicu Valcea
Russian Federation Local Institution - 0061 Ekaterinburg
Russian Federation Local Institution - 0056 Kemerovo
Russian Federation Local Institution - 0072 Novosibirsk
Russian Federation Local Institution - 0057 Orenburg
Russian Federation Local Institution - 0062 Saint - Petersburg
Russian Federation Local Institution - 0070 Smolensk
Russian Federation Local Institution - 0058 St. Petersburg
Russian Federation Local Institution - 0055 Vladimir
Russian Federation Local Institution - 0060 Yaroslavl
Russian Federation Local Institution - 0068 Yaroslavl
Spain Local Institution - 0126 Malaga
Spain Local Institution - 0138 Sabadell
Spain Local Institution - 0124 Sevilla
Taiwan Local Institution - 0052 Taichung
Taiwan Local Institution - 0051 Taipei
Taiwan Local Institution - 0137 Taipei
Taiwan Local Institution Taipei City
United States Local Institution - 0094 Atlanta Georgia
United States Local Institution - 0041 Austin Texas
United States Tekton Research - Austin Austin Texas
United States Local Institution - 0115 Aventura Florida
United States Local Institution - 0077 Birmingham Alabama
United States Local Institution - 0044 Brandon Florida
United States Local Institution - 0123 Brooklyn New York
United States Local Institution - 0071 Chapel Hill North Carolina
United States Local Institution - 0121 Charleston South Carolina
United States Local Institution - 0031 Charlotte North Carolina
United States Local Institution - 0114 Dallas Texas
United States Local Institution - 0030 El Cajon California
United States Local Institution - 0140 Gainesville Florida
United States Local Institution - 0037 Houston Texas
United States Local Institution - 0001 Jackson Tennessee
United States Local Institution - 0050 Lawrenceville Georgia
United States Local Institution - 0046 Mesquite Texas
United States Local Institution - 0074 New Haven Connecticut
United States Local Institution - 0131 New York New York
United States Local Institution - 0064 Oklahoma City Oklahoma
United States Local Institution - 0133 Orlando Florida
United States Local Institution - 0032 Ormond Beach Florida
United States Local Institution - 0048 Tampa Florida
United States Local Institution - 0049 Torrance California
United States Local Institution - 0035 Wyomissing Pennsylvania

Sponsors (1)

Lead Sponsor Collaborator
Bristol-Myers Squibb

Countries where clinical trial is conducted

United States,  Argentina,  Brazil,  Canada,  Colombia,  Hungary,  Japan,  Korea, Republic of,  Mexico,  Poland,  Romania,  Russian Federation,  Spain,  Taiwan, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of participants with Adverse Events (AEs) Up to 30 days after last treatment dose (approximately 178 weeks)
Primary Number of participants with Serious Adverse Events (SAEs) Up to 30 days after last treatment dose (approximately 178 weeks)
Primary Number of participants with AEs leading to discontinuation Up to 30 days after last treatment dose (approximately 178 weeks)
Primary Number of participants with abnormal change from baseline in laboratory measurements over time Up to 30 days after last treatment dose (approximately 178 weeks)
Primary Number of participants with abnormal change from baseline in vital signs over time Up to 30 days after last treatment dose (approximately 178 weeks)
See also
  Status Clinical Trial Phase
Terminated NCT03843125 - A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE) Phase 3
Recruiting NCT05698173 - Systemic Lupus Erythematosus and Accelerated Aging N/A
Active, not recruiting NCT01649765 - Pediatric Lupus Trial of Belimumab Plus Background Standard Therapy Phase 2
Recruiting NCT05704153 - Modelling and Control of Non-invasive Vagus Nerve Stimulation for Autoimmune Diseases (1A) N/A
Completed NCT05048238 - Evaluation of Tofacitinib in Prevention of Photosensitivity in Lupus Phase 1
Recruiting NCT06056778 - The Prevalence Evaluation of Systemic Lupus Erythematosus in Russian Patients With Reproductive Issues (PRISMA)
Completed NCT04358302 - Individual Patient Exposure and Response in Pediatric Lupus N/A
Completed NCT03802578 - The Impact of Exercise on Hand Function, Daily Activities Performance and Quality of Life of SLE' Patients N/A
Completed NCT02554019 - Proof-of-Concept Study With BT063 in Subjects With Systemic Lupus Erythematosus Phase 2
Recruiting NCT04835883 - Exploring the Efficacy and Safety of CS20AT04 (Allogenic Bone Marrow-Derived Stem Cell) in Systemic Lupus Erythematosus Patients Phase 2
Terminated NCT02665364 - Phase IIb Study of IFN-K in Systemic Lupus Erythematosus Phase 2
Completed NCT00278538 - Cyclophosphamide and Rabbit Antithymocyte Globulin (rATG)/Rituximab in Patients With Systemic Lupus Erythematosus Phase 2
Completed NCT00069342 - Health Beliefs and Health Behaviors Among Minorities With Rheumatic Diseases
Completed NCT03252587 - An Investigational Study to Evaluate BMS-986165 in Participants With Systemic Lupus Erythematosus Phase 2
Terminated NCT02066311 - Nelfinavir in Systemic Lupus Erythematosus Phase 2
Recruiting NCT01892748 - Cholecalciferol Supplementation on Disease Activity, Fatigue and Bone Mass on Juvenile Systemic Lupus Erythematosus. N/A
Terminated NCT01689025 - An Investigation of Safety and Tolerability of NNC0114-0006 in Subjects With Systemic Lupus Erythematosus (SLE) Phase 1
Completed NCT01475149 - Effect of HCQ on AnxA5 Resistance Assay in Antiphospholipid (aPL) Positive Patients With and Without Systemic Lupus Erythematosus (SLE) N/A
Unknown status NCT01712529 - Physical Exercise, Endothelial Function and Progenitor Endothelial Cells in Systemic Lupus Erythematosus Patients N/A
Completed NCT00962832 - A Study to Evaluate the Efficacy and Safety of Rontalizumab in Patients With Moderately to Severely Active Systemic Lupus Erythematosus Phase 2